Investors are jumping in ahead of a data presentation tomorrow.
News & Analysis: Lexicon Pharmaceuticals
The company will receive a big windfall for a terminated collaboration. What happens next?
It’s rejected a pair of drugs in the last six months.
Earnings and other woes weighed on these stocks.
Sanofi is walking away from an important collaboration, leaving shareholders wondering what's next.
LXRX earnings call for the period ending March 31, 2019.
American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.
Poor prospects and a big disappointment hit these stocks.
LXRX earnings call for the period ending December 31, 2018.
European experts don't have the same concerns over the company's lead drug as their American peers, recommending it for patients with type 1 diabetes.